Related Experiment Video

Updated: Apr 21, 2026

Quantifying the Cytotoxicity of Staphylococcus aureus Against Human Polymorphonuclear Leukocytes
12:27

Quantifying the Cytotoxicity of Staphylococcus aureus Against Human Polymorphonuclear Leukocytes

Published on: January 3, 2020

8.4K

[Analysis of serum vancomycin concentration after administration of different doses in children with Staphylococcus

Guang-Li Zhang1, Hui Zhamg, Ru Liu

  • 1Department of Respiratory Disease, Children′s Hospital, Chongqing Medical University, Chongqing 400014, China. luozhengxiu816@163.com.

Zhongguo Dang Dai Er Ke Za Zhi = Chinese Journal of Contemporary Pediatrics
|October 26, 2014
PubMed

Insights

A dosage of 15 mg/(kg·dose) every 6 hours (q6h) of vancomycin is recommended for pediatric Staphylococcus aureus pneumonia (SAP). This dose achieved higher serum vancomycin trough concentrations compared to lower doses, improving treatment efficacy.

Area of Science:

  • Pediatric Infectious Diseases
  • Pharmacokinetics and Pharmacodynamics
  • Antibiotic Therapy

Context:

  • Staphylococcus aureus pneumonia (SAP) is a serious infection in children.
  • Vancomycin is a critical antibiotic for treating resistant bacterial infections.
  • Optimizing vancomycin dosing is essential for effective treatment and minimizing toxicity.

Purpose:

  • To determine the appropriate vancomycin dosage for pediatric patients with Staphylococcus aureus pneumonia (SAP).
  • To analyze serum vancomycin concentrations at different therapeutic doses.
  • To correlate dosage with achieving target serum trough concentrations.

Summary:

  • Retrospective analysis of 35 pediatric SAP cases treated with vancomycin.
  • Evaluated vancomycin doses of 10, 12.5, and 15 mg/(kg·dose) every 6 hours (q6h).
  • The 15 mg/(kg·dose) q6h dose resulted in significantly higher mean serum trough concentrations (14.98 mg/L) and a higher percentage of patients reaching therapeutic targets (71%) compared to lower doses.

Impact:

  • Establishes 15 mg/(kg·dose) q6h (or 60 mg/(kg·d)) as a reasonable vancomycin dosage for pediatric SAP.
  • Provides evidence-based guidance for optimizing vancomycin therapy in children.
  • Aims to improve treatment outcomes and reduce the risk of treatment failure or adverse events.
Abstract

More Related Videos

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials06:18

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials

Published on: March 3, 2023

4.4K
Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

7.7K

Related Concept Videos

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
377
Estimation of k and VD of Aminoglycosides01:20

Estimation of k and VD of Aminoglycosides

Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
328
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
395
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
391
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
532
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
972